OpenURL Connection Search

Select item for more details and to access through your institution.

Leukotriene B<sub>4</sub> receptor type 2 protects against pneumolysin-dependent acute lung injury.
Published in:
Scientific Reports, 2016, p. 34560, doi. 10.1038/srep34560
By:
- Shigematsu, Misako;
- Koga, Tomoaki;
- Ishimori, Ayako;
- Saeki, Kazuko;
- Ishii, Yumiko;
- Taketomi, Yoshitaka;
- Ohba, Mai;
- Jo-Watanabe, Airi;
- Okuno, Toshiaki;
- Harada, Norihiro;
- Harayama, Takeshi;
- Shindou, Hideo;
- Li, Jian-Dong;
- Murakami, Makoto;
- Hoka, Sumio;
- Yokomizo, Takehiko
Publication type:
Article
Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E.
Published in:
Allergy, Asthma & Clinical Immunology, 2018, v. 14, n. 1, p. N.PAG, doi. 10.1186/s13223-018-0300-7
By:
- Yasuda, Mina;
- Harada, Norihiro;
- Harada, Sonoko;
- Ishimori, Ayako;
- Katsura, Yoko;
- Itoigawa, Yukinari;
- Matsuno, Kei;
- Makino, Fumihiko;
- Ito, Jun;
- Ono, Junya;
- Tobino, Kazunori;
- Akiba, Hisaya;
- Atsuta, Ryo;
- Izuhara, Kenji;
- Takahashi, Kazuhisa
Publication type:
Article
Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma.
Published in:
Biomolecules (2218-273X), 2023, v. 13, n. 3, p. 538, doi. 10.3390/biom13030538
By:
- Sandhu, Yuuki;
- Harada, Norihiro;
- Sasano, Hitoshi;
- Harada, Sonoko;
- Ueda, Shoko;
- Takeshige, Tomohito;
- Tanabe, Yuki;
- Ishimori, Ayako;
- Matsuno, Kei;
- Abe, Sumiko;
- Nagaoka, Tetsutaro;
- Ito, Jun;
- Chiba, Asako;
- Akiba, Hisaya;
- Atsuta, Ryo;
- Izuhara, Kenji;
- Miyake, Sachiko;
- Takahashi, Kazuhisa
Publication type:
Article

Found: 3

Leukotriene B<sub>4</sub> receptor type 2 protects against pneumolysin-dependent acute lung injury.

Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E.

Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma.